Showing 42,681 - 42,700 results of 61,561 for search '(( 50 a decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (nn decrease)) ))', query time: 1.11s Refine Results
  1. 42681

    DataSheet_1_A comparative study of adjuvants effects on neonatal plasma cell survival niche in bone marrow and persistence of humoral immune responses.docx by Audur Anna Aradottir Pind (7431725)

    Published 2022
    “…Furthermore, we performed a comparative analysis of the potential of 5 different adjuvants; LT-K63, mmCT, MF59, IC31 and alum, to enhance expression of survival factors and BCMA following immunization of neonatal mice with tetanus toxoid (TT) vaccine. …”
  2. 42682

    DataSheet_3_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.csv by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  3. 42683

    DataSheet_8_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.csv by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  4. 42684

    DataSheet_7_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.csv by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  5. 42685
  6. 42686

    DataSheet_1_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.csv by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  7. 42687

    DataSheet_2_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.csv by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  8. 42688

    Na/K-ATPase signaling mediates miR-29b-3p regulation and cardiac fibrosis formation in mice with chronic kidney disease by Christopher A. Drummond (3845110)

    Published 2018
    “…Using isolated cardiac fibroblasts from α1+/- mice and their WT littermates, we showed that ouabain, a specific Na/K-ATPase ligand, induces decreased miR-29b-3p expression in fibroblasts isolated from WT mice, but had no effect in cells from α1+/- mice. …”
  9. 42689

    Table_2_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.docx by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  10. 42690

    DataSheet_4_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.csv by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  11. 42691

    DataSheet_6_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.csv by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  12. 42692

    Table_1_Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.docx by Changwei Zheng (13928844)

    Published 2022
    “…Single nucleotide polymorphisms (SNPs) were chosen as instrumental variables (IVs). We obtained genetic variants associated with lipid exposure at the genome-wide significance (P<5×10<sup>−8</sup>) level from a meta-analysis of GWAS from the Global Lipids Genetics Consortium (GLGC) based on 188,577 individuals of mostly European ancestry for MR analyses. …”
  13. 42693

    Six Year Refractive Change among White Children and Young Adults: Evidence for Significant Increase in Myopia among White UK Children by Sara J. McCullough (846708)

    Published 2016
    “…The proportion of myopes in the UK has more than doubled over the last 50 years in children aged between 10–16 years and children are becoming myopic at a younger age. …”
  14. 42694

    Illustrative cases of fractionated radiosurgery for large brain metastases. by Joo Whan Kim (3135003)

    Published 2016
    “…<p>A 50-year-old woman was diagnosed with brain metastases 4 years after treatment for breast cancer. …”
  15. 42695
  16. 42696

    Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals by Zari Dastani (144367)

    Published 2012
    “…We identified 8 novel loci associated with adiponectin levels and confirmed 2 previously reported loci (<em>P</em> = 4.5×10<sup>−8</sup>–1.2×10<sup>−43</sup>). …”
  17. 42697

    datasheet1_Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.docx by Yue Sun (197395)

    Published 2020
    “…As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). …”
  18. 42698

    datasheet1_Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.docx by Yue Sun (197395)

    Published 2021
    “…As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). …”
  19. 42699
  20. 42700